What is Johnson & Johnson's rybrevant + lazcluze — percent change (as a percent)?

Johnson & Johnson (JNJ) reported rybrevant + lazcluze — percent change (as a percent) of 82.7% in Q1 2026.

What does rybrevant + lazcluze — percent change (as a percent) mean?

The percentage growth rate of revenue from the Rybrevant and Lazcluze oncology product line.

Products & Services · Percent Change (as a percent)

RYBREVANT + LAZCLUZE — Percent Change (as a percent)

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2026

Last reportedQ1 2026

How to read this metric

An increase indicates strong market uptake and successful commercial execution for these specific oncology treatments, while a decrease may signal slowing demand, increased competition, or market saturation.

Detailed definition

This metric measures the period-over-period percentage growth in revenue generated by the combined Rybrevant and Lazcluz...

Peer comparison

Comparable to revenue growth rates for specific high-growth oncology or specialty pharmaceutical franchises at peer biopharmaceutical companies.

Metric ID: jnj_segment_rybrevant_lazcluze_percent_change_as_a_percent

Historical Data

1 periods

	Q1 '26
Value	82.7%

Similar Metrics at Other Companies

BiogenBIIB View metric

Natera, Inc.NTRA View metric

Gilead SciencesGILD View metric

Frequently Asked Questions

What is Johnson & Johnson's rybrevant + lazcluze — percent change (as a percent)?: Johnson & Johnson (JNJ) reported rybrevant + lazcluze — percent change (as a percent) of 82.7% in Q1 2026.
What does rybrevant + lazcluze — percent change (as a percent) mean?: The percentage growth rate of revenue from the Rybrevant and Lazcluze oncology product line.